Beyond the image: New opportunities in
gynecologic cancer testing
Industry Supported Symposium

Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) has emerged as a promising tool for improving the management of gynecologic malignancies, including endometrial, ovarian, and cervical cancers. This 90-minute course explores the evolving role of ctDNA in identifying disease recurrence and assessing treatment response—potentially earlier than imaging or traditional biomarkers.

Participants will receive an in-depth overview of the biological basis of ctDNA detection, the current clinical evidence supporting its utility, and its integration into clinical workflows. Case-based discussions will illustrate real-world applications, showcasing how ctDNA can optimize decisions on surveillance and therapeutic strategy. The program will also critically assess limitations and challenges of ctDNA-based MRD testing, including issues with sensitivity, false positives, access, and cost.

In alignment with a fair and balanced approach, the course will also explore other MRD detection modalities such as radiologic imaging, CA-125, and histopathology, highlighting comparative strengths and contexts for use. The program engages clinicians to learn how to interpret ctDNA MRD data and apply it effectively within a multidisciplinary care framework.

This educational activity is supported by an independent medical education grant from Natera Therapeutics, Inc.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will be able to:

• Describe the principles of MRD testing using circulating tumor DNA (ctDNA) and its application in gynecologic cancers.
• Compare ctDNA-based MRD monitoring with traditional methods such as imaging and serum biomarkers.
• Evaluate the evidence for ctDNA use in detecting recurrence and guiding treatment decisions in endometrial, ovarian, and cervical cancers.
• Discuss limitations, alternative approaches, and considerations for integrating MRD testing into clinical practice.